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EXPRESSION OF PROTECTIVE ANTIGENS
IN TRANSGENIC CHLOROPLASTS

an additive protective effect when used to immunize humans
against plague. It is thought that Fl-V fusion protein should
provide protection against both subcutaneous and aerosol
challenge, and will have the potential to provide protective
immunity against pneumonic as well as bubonic plague due
to either wild type Fl+ Y. pestis or to naturally occurring
Fl-variants. To date no one has been able to express the
Fl-V fusion protein in transgenic chloroplast. Such an
accomplishment would provide a large supply of highquality antigen for vaccines.

BACKGROUND
Yersinia pestis is the causative agent of bubonic and
pneumonic plague. Bacillus anthracis is the causative agent
for the anthrax disease. The Centers for Disease Control and
Prevention (hereinafter "CDC") lists Y. pestis and B. anthracis as two of the six Category A biological agents that pose
a risk to national security.
Yersinia pestis
The etiologic agent of plague is the Gram-negative bacterium Yersinia pestis. The natural route of transmission of
Y. pestis from one animal host to another is either directly or
via a flea vector. Plague is endemic in some regions of the
world and outbreaks occasionally occur as a consequence of
natural disasters. Y. pestis is also a concern as one of the
microorganisms with potential for use against civilian or
military populations as a biological warfare/biological terrorism agent. In such a situation, the pneumonic form of
plague would be the most likely outcome. This form of
plague is particularly devastating because of the rapidity of
onset, the high mortality, and the rapid spread of the disease.
Immunization against aerosolized plague presents a particular challenge for vaccine developers. There is currently no
vaccine for plague.
Both live attenuated and killed plague vaccines have been
used in man, although questions remain about their safety
and relative efficacy, especially against the pneumonic form
of infection. Since plague remains endemic in some regions
of the world, and because of the possibility of the illegitimate use of Y. pestis as a biological warfare agent, development of improved vaccines against plague is a high
priority. The ideal vaccine should be deliverable in a minimum of doses and quickly produce high titer and longlasting antibodies. Moreover, such a vaccine should protect
against aerosolized transmission of Y. pestis.
The two most recently described approaches to development of improved plague vaccines are 1) attenuated mutants
of Y. pestis and 2) subunit vaccines. The potential efficacy of
attenuated mutants of Y. pestis as vaccines is supported by
experience with the live attenuated vaccine strain EV76.
This vaccine has been in use since 1908 and is given as a
single dose Immunization of mice with EV76 induces an
immune response and protects mice against subcutaneous
and inhalation (aerosolized) infection. However, this vaccine strain is not avirulent and has an unacceptable safety
profile. Moreover, multiple variants of the classical EV76
strain exist that differ significantly in passage history and
genetic characteristics. Recent studies have focused on creating defined genetically attenuated mutants of Y. pestis,
similar to those created in other Gram-negative bacteria (i.e.,
Salmonella spp.). For unknown reasons, genetic mutations,
which markedly attenuate Salmonella spp. do not attenuate
Y. pestis. For instance, an aroA mutant of Y. pestis was fully
virulent in the murine model of disease but avirulent in
guinea pigs.
A number of potential subunit vaccines have been evaluated for immunogenicity and protective efficacy against Y.
pestis. The two most promising are Fl and V. Fl is a capsular
protein located on the surface of the bacterium and the V
antigen is a component of the Y. pestis Type III secretion
system. These proteins have been produced recombinantly
and induce protective immune responses when administered
individually. A combination or fusion of F 1 and V may have
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Bacillus anthracis
Bacillus anthracis is the organism that causes the anthrax
disease. It is a Gram-positive, nonmotile, aerobic or facultatively anaerobic, spore-forming bacterium. The spores are
about 1 µm in size, extremely hardy, resistant to ganima
rays, UV light, drying, heat, and many disinfectants. Spores
germinate upon entering an environment rich in glucose,
amino acids, and nucleosides, such as in animal and human
tissues and blood. The vegetative cells enter the spore state
when the nutrients are exhausted or when the organisms are
exposed to molecular oxygen in the air.
Anthrax is typically a disease of animals, especially
herbivores such as cows, sheep, and goats. It affects humans
through contact with the spores in one of three ways.
Cutaneous anthrax occurs when the spores enter the body
through a cut or an abrasion on the skin. Gastrointestinal
anthrax occurs when the spores enters the body through
consumption of contaminated meat products. Inhalation
anthrax occurs when the spores enter the body through
inhalation of the spores.
When spores enter the body, macrophages engulf them,
migrate to regional lymph nodes and the spores germinate
into vegetative bacteria. Macrophages release the vegetative
bacteria and they spread through the blood and lymph until
there are up to 10 8 bacilli per milliliter of blood. The
exotoxins are produced from bacteria and they lead to
symptoms and possible death. Spores can survive in the
lungs or lymph nodes up to 60 days before germination
occurs. In animal experiments, it has been seen that once
toxin secretion has reached a critical threshold, death will
occur, even if the blood is rendered sterile through the use
of antibiotics. From primate studies, the estimated lethal
dose of inhaled anthrax spores sufficient to kill 50% of
humans exposed to it (the LD50) is 2,500-55,000 spores.
The CDC lists anthrax as a category A disease agent and
estimates the cost of an anthrax attack would be $26.2
billion per 100,000 persons exposed. The only vaccine
licensed for human use in the U.S., Biothrax (formerly
Anthrax vaccine adsorbed, or AVA), is an aluminum hydroxide-adsorbed, formalin-treated culture supernatant of a toxigenic, nonencapsulated, non-proteolytic strain of Bacillus
anthracis. In addition to the immunogenic protective antigen
(PA), the vaccine contains trace amounts of edema factor
(EF) and lethal factor (LF) that may contribute to the local
reactions seen in 5-7% of vaccine recipients, or reported to
be toxic causing side-effects. There is a clear need and
urgency for an improved vaccine for anthrax and for
improved production methods that allow it to be massproduced at reasonable cost.
There are two main virulence factors associated with B.
anthracis, the polyglutamyl capsule which is believed to
prevent the vegetative bacterial cells from being phagocytized and the exotoxins. Two different exotoxins are produced by three factors. PA binds to the host cell, LF is a zinc
metalloprotease which inactivates mitogen-activated protein
kinase. The edema toxin is formed when PA binds to EF.
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This toxin increases cyclic AMP (cAMP) levels in the cell
which upsets the water homeostasis resulting in accumulation of fluid called edema. The lethal toxin is formed from
binding of PA and LF. This toxin stimulates macrophages to
release interleukin-I b, tumor necrosis factor a, and other
cytokines which contribute to shock and sudden death.
Anthrax has become a serious threat due to its potential
use in bioterrorism and recent outbreaks among wild-life in
the United States. Concerns regarding vaccine purity, the
current requirement for six injections followed by yearly
boosters, and a limited supply of the key protective antigen
(PA), underscore the urgent need for an improved vaccine.

supernatant fraction, "Hom" means homogenate (soluble
and insoluble fractions). The construct used was pLD-JW2.
FIG. 4 shows western blots of T 1 pLD-JWl plant in
continuous light in FIGS. 4A and 4B, and in FIG. 4C shows
histogram of µg PA/g fresh tissue in young, mature, and old
leaves after 3 and 5 days of continuous illumination.
FIG. S shows graphs of the results of macrophage cytotoxic assays for extracts from transgenic plants. FIG. SA
shows supernatant and homogenate samples from T 0 pLDJWl tested. FIG. SB shows Supernatant samples from T 1
pLD-JWl tested.
FIG. 6A is a schematic view of tomato vector construct
pLD Tom-BADH, while FIG. 6B shows PCR for transformants using 3P/3M primers of the pLD-TOM-BADH
tomato vector.
FIG. 7 is a schematic of the pTOM-BADH2-G10-pag
tomato vector construct
FIG. 8 shows PCR analysis of the products of tomato
vectors using BADH primers, wherein+ is pTOM-GlO-PA
vector control, - is WT Tomato plant, and # 3 is transgenic
tomato plant.
FIG. 9A shows tomato seedlings 12 days after seed
germination, while 9B shows tomato cotyledons ready for
bombardment.
FIG. 10 shows cut and bombarded cotyledons.
FIGS. llAand B show the response of tomato cotyledons
transformed with the pLD-TOM-BADH on RMOP supplemented with 2.5 nm betaine aldehyde, where wild type is
illustrated in lla and putative transformant in llb.
FIG.12 shows the serum anti-PA as determined by ELISA
and the in vitro toxin neutralization by serum antibodies
following intranasal immunization.
FIG. 13A is a schematic view of a pLDS-FlV vector
construct, while FIG. 13B shows restriction enzyme analysis
of the pLDS-Fl V vector.
FIG. 14A shows PCR reactions to determine pLDS-FlV
vector integration into the chloroplast genome of Petit
Havana, while 14B shows a second PCR reaction, which is
also used to determine pLDS-Fl V transgene integration.
FIG. lSA shows a Western Blot of pLDS-FlV from
XLl-Blue strain of Ecoli, while lSB shows Western Blots of
FlV expression in transgenic chloroplasts.
FIG. 16 is a schematic of constructs to be inserted in
edible plants, where "gene X" represents each of LF27PA63, CTB-LF27, LF27-PA63+CTB-LF27, LF27+PA.
FIG. 17A is a schematic view of a pDD34-ZM-gfpBADH vector construct, while 17B shows the subsequent
expression of the construct containing GFP in E.coli,
FIG. 18A is a schmetactic of pDD33-ZM-aadA-BADH
vector construction, and 18B shows the subsequent expression of the construct in E.coli grown on spectinomycin.
FIG. 19(A-C) show GFP expression in embryogenic
maize cultures where a is non-transgenic control and b and
c are transformed maize embryonic calli.
FIG. 20A shows maize control and transgenic plants on
regeneration medium containing spectomycin, while FIG.
20B shows PCR confirmation of chloroplast transgenic
plants using appropriate primers.
FIG. 21Ais a schematic view ofa pDD37-DC-gfp-BADH
carrot chloroplast transformation vector, while 21B illustrates GFP expression in E.coli.
FIG. 22A is a schematic of a vector construct pDD36-DC
aadA-BADH carrot chloroplast transformation vector, while
22B illustrates the expression of the vector using E.coli cells
grown on spectinomycin.
FIG. 23 (A-D) shows Expression of GFP in different
stages of transgenic cultures of carrot.
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SUMMARY OF THE INVENTION
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The present invention pertains to vaccines for conferring
immunity in mammals to infective pathogens, as well as
vectors and methods for plastid transformation of plants to
produce protective antigens and vaccines for oral delivery.
The invention further provides transformed plastids having
the ability to survive selection in both the light and the dark,
at different developmental stages by using genes coding for
two different enzymes capable of detoxifying the same
selectable marker, driven by regulatory signals that are
functional in proplastids as well as in mature chloroplasts.
The invention utilizes antibiotic-free selectable markers to
provide edible vaccines for conferring immunity to a mammal against Bacillus anthracis, as well as Yersina pestis. The
vaccines are operative by parenteral administration as well.
The invention also extends to the transformed plants, plant
parts, and seeds and progeny thereof. The invention is
applicable to monocot and dicot plants.
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FIG. 1 is a schematic view of anthrax chloroplast constructs according to the present invention, and a view of a
southern blot. FIG. lA shows the pLD-JWl vector used for
chloroplast transformation. FIG. lB shows the pLD-JW2
construct. FIG. lC shows PCR with the primers 3P and 3M.
FIG. lD shows a PCR analysis of randomly selected clones.
FIG. 2 is a schematic view of anthrax chloroplast constructs according to the present invention, and views of
southern blots. FIG. 2A shows expected products from
digestion of wild type untransformed plant. FIG. 2B shows
expected products from digestion of a plant transformed
with pLD-JWl. FIG. 2C shows expected products from
digestion of a plant transformed with pLD-JW2. FIG. 2D
shows a flanking sequence probe showing heteroplasmy in
pLD-JWl line and homoplasmy in pLD-JW2 lines. FIG. 2E
shows a pag sequence probe showing presence of pag in
transgenic lines.
FIG. 3 shows Western blots demonstrating PA expression
of transgenic lines containing different constructs. FIG. 3A
shows a western blot of pLD-JWl T 1 transgenic lines for PA
quantification. Lane 1: wild type; Lane 2: Ladder; Lane 3: 20
ng PA; Lane 4: 10 ng PA; Lane 5: 5 ng PA; Lane 6: 1:10
dilution pLD-JWl line; Lane 7: 1:20 dilution pLD-JWl line.
FIG. 3B shows a western blot of pLD-JW2 T 1 transgenic
lines for PA quantification. Lane 1: wild type; Lane 2:
Ladder; Lane 3: 20 ng PA; Lane 4: 10 ng PA; Lane 5: 5 ng
PA; Lane 6: blank; Lane 7: 1:10 dilution pLD-JW2 line #1;
Lane 8: 1:20 dilution pLD-JW2 line #1; Lane 9: 1:10
dilution pLD-JW2 line #2; Lane 10: 1:20 dilution pLD-JW2
line #2. FIG. 3C shows a western blot comparing extraction
buffers, containing CHAPS and SDS, and both, and measuring stability of extracts at 4 ° C., where "Sup" means
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FIG. 24 is a schematic view of a Double Barreled Plastid
Vector harboring aphA-6 and aphA-2 genes conferring resistance to aminoglycosides according to the present invention.

6

plasts. Chloroplasts are prokaryotic in nature and express
native bacterial genes (like B subunit of cholera toxin) at
very high levels (410-fold higher than nuclear expression).
Production in chloroplasts is in sharp contrast to nuclear
DETAILED DESCRIPTION OF THE
expression, that often requires extensive codon modificaINVENTION
tions because of high AT content, unfavorable codons,
presence of mRNA destabilizing sequences, and cryptic
polyadenylation or splice sites. Chloroplast transformation
Chloroplast Engineering
typically utilizes two flanking sequences that, through
The concept of chloroplast genetic engineering, allows
10 homologous recombination, insert transgenes into spacer
the introduction of isolated intact chloroplasts into protoregions between functional genes of the chloroplast genome,
plasts and regeneration of transgenic plants. Early investithus targeting transgenes to a known location. This elimigations involving chloroplast transformation focused on the
nates the "position effect" and gene silencing frequently
development of in organello systems using intact chloroobserved in nuclear transgenic plants. Chloroplast genetic
plasts capable of efficient and prolonged transcription, trans15 engineering is an environmentally friendly approach, minilation, and expression of foreign genes in isolated chloromizing concerns of out-cross of introduced traits via pollen
plasts. However, the discovery of the gene gun as a
to weeds or other related crops. The chloroplast genome may
transformation device made it possible to transform plant
be engineered without the use of antibiotic resistant genes as
chloroplasts without the use of isolated plastids and protowell for the development of edible vaccines. The term
plasts. Chloroplast genetic engineering has been accom20 "edible vaccine" as used herein refers to a substance which
plished in several phases. Studies have been made on the
may be given orally which will elicit a protective immunotransient expression of foreign genes in plastids of monocots
genic response in a manmial.
and dicots. Unique to the chloroplast genetic engineering is
The difficulty of engineering the chloroplast genome
the development of a foreign gene expression system using
autonomously replicating chloroplast expression vectors. 25 without antibiotic resistant genes has recently been overcome by modifying chloroplasts without these genes. EngiStable integration of a selectable marker gene into the
neering genetically modified crops without these genes
tobacco chloroplast genome was also accomplished using
eliminates their potential transfer to the environment and to
the gene gun. Recently, useful genes conferring valuable
microbes in the gut. Antibiotic-free selection can be accomtraits via chloroplast genetic engineering have been demonstrated. Plants resistant to Bacillus thuringiensis (Bt) sensi- 30 plished by using the betaine aldehyde dehydrogenase
(BADH) gene from spinach as a selectable marker. Specifitive and resistant insects were obtained by integrating the
cally, the Applicant's published application, WOOl/64023,
cryIAc and cry2A genes into the tobacco chloroplast
which is hereby incorporated by reference, demonstrates
genome.
using an antibiotic free selectable marker. The selection
Chloroplast genomes of plants have also been genetically
process involves conversion of toxic betaine aldehyde (BA)
engineered to confer herbicide resistance where the intro- 35
to non-toxic glycine betaine, which also serves as an osmoduced foreign genes were maternally inherited. This was a
protectant and helps confer drought tolerance.
significant step in the development of commercially viable
The Applicant has transformed the chloroplast of edible
genetically modified plants because it alleviates any conmonocot
and dicot species, as is illustrated in the accompacerns over the problem of out-crossing traits with weeds or
40 nying Figures. Specifically, the figures illustrate the stable
other crops.
transformation of carrot and corn chloroplast genomes,
For large-scale foreign protein production, plants are an
which has not previously been accomplished. The transforideal choice due to the relative ease of genetic manipulation,
mation of carrot, tomato, and corn allow the production of
rapid scale up (million seeds per plant), large biomass, and
edible vaccines. These transformed plants also allow the
the potential to find alternative uses for various crops. A
purification
and use of the antigens produced by these plants
remarkable feature of chloroplast genetic engineering is the 45
as high purity parenteral vaccines. However, the production
observation of exceptionally large accumulation of foreign
of edible vaccines is preferred for their ease of use and low
proteins in transgenic plants (as much as 46% of CRY
cost.
protein in total soluble protein) even in bleached old leaves.
FIGS. 17A and 18A illustrate the construction of maize
Using chloroplast transformation technology, large quantities of protective antigen can be produced in transgenic 50 chloroplast transformation vector, where flanking regions
were amplified using PCR. The PCR products were cloned
plants, due to the presence of thousands of copies of
and the expression cassette was inserted in the transcriptransgenes per cell as opposed to only a few copies in
tionally active spacer region between trnI/trnA genes. The
nuclear transgenic plants. By "protective antigen" is meant
expression cassette of FIG. 17A has the Prrn promoter
that the antigen elicits an immunogenic response in mammals when administered by an appropriate route in an 55 driving the expression of GFP and BADH, which are regulated by (5') gene10/rps16 3' and psbA 5'/3' UTRs respecappropriate amount. Transgenic chloroplast technology has
tively. The expression cassette of 18A has the Prrn promoter
been used to hyper-express bacterial proteins-up to 46% of
driving the expression of aadA and BADH. The latter gene
total soluble protein from Bacillus genes, the highest ever
is regulated by (5') gene10/rps16 3' UTRs.
reported in transgenic plants. However, large heterologous
Functions of the genes in the carrot chloroplast transforproteins are not always processed correctly. Furthermore, 60
such proteins are subject to attack by proteolytic enzymes
mation vectors were tested in E. coli. For observing GFP
after formation. The cholera toxin B subunit is about 11
expression, cells were plated on LB agar (Amp) plates and
incubated at 37° C. overnight. Cells harboring pDD34-ZMkilodaltons in size. The anthrax protective antigen is about
83 kd in size, presenting a significant challenge to producGFP-BADH were seen to fluoresce when exposed to UV
tion in a chloroplast. A similar challenge is presented by the 65 light, as is seen in FIG. 17B. To test the aadA gene
F 1-V antigen, which is a fusion protein. Such fusion proteins
expression, cells harboring pDD33-ZM-aadA-BADH plashave not heretofore been successfully expressed in chloromid were plated on LB agar plates containing spectinomycin
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(100 mg/ml) and incubated at 37° C. overnight. Transformed
cells grow on spectinomycin, as can be seen in FIG. 18B.
FIG. 19 shows GFP expression in embryogenic maize
cultures studied under the confocal microscope. FIG. 19A is
a non-transgenic control, while FIG. 19B-C are transformed
maize embryogenic calli.
The selection in FIG. 19 was initiated two days after
bombardment by transferring the bombarded calli to callus
induction medium containing BA or streptomycin. After
eight weeks, a number of the healthy growing calli from
different bombardment experiments were examined for GFP
expression under the fluorescent stereomicroscope and the
confocal microscope. Somatic embryos were regenerated on
maize regeneration medium containing BA or streptomycin.
FIG. 20A shows maize plants on regeneration medium
containing streptomycin or betaine aldehyde. FIG. 20A
illustrates maize chloroplast transgenic plants which were
capable of growth on the selection agent indicating that
construction of transgenic maize, while untransfomed maize
plants did not grow on the selection medium.
FIG. 20B shows PCR confirmation of chloroplast transgenic plants using appropriate primers. Lanes 1-3, plants
transformed with pDD34-ZM-gfp-BADH and Lanes 4-5,
plants transformed with pDD33-ZM-aadA-BADH. Lanes and + represent the negative and positive controls respectively. Genomic DNA was isolated from the leaf tissues and
PCR was performed on transformed and non-transformed
tissues using appropriate primers.
FIGS. 21A and 22A show the schematic construction of
carrot chloroplast transformation vectors. The construction
of the carrot chloroplast transformation vector illustrated in
FIGS. 21A and 22A have flanking regions that were amplified using PCR. The PCR products were then cloned and the
expression cassette was inserted in the transcriptionally
active spacer region between trnI/trnA genes. The expression cassette of FIG. 21A has the Prrn promoter driving the
expression of GFP and BADH, which are regulated by (5')
gene10/rps16 3' and psbA 5'/3' UTRs respectively. The
expression cassette of FIG. 22A has the Prrn promoter
driving the expression of aadA and BADH. The latter gene
is regulated by (5') gene10/rps16 3' UTRs.
Functions of the genes in the carrot chloroplast transformation vectors were tested in E. coli. For observing GFP
expression, cells were plated on LB agar (Amp) plates and
incubated at 37° C. overnight. Cells harboring pDD37-DCGFP-BADH were seen to fluoresce when exposed to UV
light (A). To test the aadA gene expression, cells harboring
pDD36-DC-aadA-BADH plasmid were plated on LB agar
plates containing spectinomycin (100 mg/ml) and incubated
at 37° C. overnight. Transformed cells grow on spectinomycin (B).
Functions of the genes in the carrot chloroplast transformation vectors were tested in E. coli. For observing GFP
expression, cells were plated on LB agar (Amp) plates and
incubated at 37° C. overnight. Cells harboring pDD34-ZMGFP-BADH were seen to fluoresce when exposed to UV
light as is seen in FIG. 21B. To test the aadA gene expression, cells harboring pDD33-ZM-aadA-BADH plasmid
were plated on LB agar plates containing spectinomycin
(100 µg/ml) and incubated at 37° C. overnight. Transformed
cells grow on spectinomycin, as is seen in FIG. 22B.
FIG. 23 (A-D) shows expression of GFP in different
stages of transgenic carrot cultures studied under confocal
microscope (A) Untransformed control, (B) Embryogenic
callus, (C) Embryogenic callus differentiated into globular
somatic embryos and (D) Somatic embryo with differentiated cotyledons.

The aforementioned transformation of maize and carrot
chloroplast provides a novel approach for improved vaccines with the creation of an edible vaccine, which provides
a heat stable environment, allows easy administration at
lower cost, and stimulates the mucosa! and systemic
immune responses. There still remain a number of hurdles
which need to be overcome, such as the fact that protective
antigens tend to be very large and unstable proteins (83
kDa); such large proteins have never been expressed before
in transgenic chloroplasts, and to date the Applicant is
unaware of the expression and assembly of heptamers in
transgenic chloroplasts.
Based upon the vector construct described above and
set-forth in further detail in this application, it is possible to
have a general construct in edible plants where it can be
determined through experimentation which construct can
elicit the strongest immune response to bacterial toxin
challenges such as, but not limiting, plague or anthrax. As an
example, FIG. 16 offers a schematic of a construct as an
example of construct which could elicit an immune response
to anthrax where, in this non-limiting example, gene X is
chosen from; 1) LF27-PA63; 2) CTB-LF27; 3) LF27-PA63+
CTB-LF27; 4) LF27+PA. These antigens derived from these
genes have been shown to elicit the immune response to
anthrax. It is noted however that a number of known genes,
which code for a bacterial antigen could be utilized in the
construct.
Edible vaccines are heat stable unlike conventional vaccines which tend to be heat sensitive. An edible vaccine has
a longer shelf life and does not require expensive refrigeration equipment. The heat sensitivity of the conventional
vaccine makes it expensive, capricious and destination limited with a series of refrigeration steps during the transportation process from manufacture to final destination.
Another major cause for the high cost of biopharmaceutical
production is purification; for example, during insulin production, chromatography accounts for 30% of the production cost and 70% of the set up cost. Therefore, oral delivery
of properly folded and fully functional biopharmaceuticals
could potentially reduce production costs by 90%. In one
study it was estimated that the banana could deliver a
vaccine (Hepatitis B) at two cents per dose compared to
approximately $125 per dose for conventional Hepatitis B
vaccine injection. Bioencapsulation of pharmaceutical proteins within plant cells offers protection against digestion in
the stomach while allowing successful delivery. In three
human clinical trials performed with plant derived vaccines,
plant cells proved sufficient for vaccinogen protection
against digestion, and the resulting vaccinogen induced
systemic and mucosa! immune responses without the aid of
adjuvants. Oral administration of PA has also been reported
to offer protection against B. anthracis using an attenuated
Salmonella strain expressing PA. However, in all these
studies the limitation is the low levels of antigen expression
which is overcome by the present invention.
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Chloroplast Transformation
It should be understood that the examples set forth herein
are non-limiting examples, and the vectors can be used on a
number of plants. The following description is capable of
being utilized as illustration and guide work for transformation of plants to express any bacterial antigen gene. It can
also be used to express viral antigen genes.
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Example 1

Transgene Integration into the Chloroplast Genome by PCR
Analysis:
Chloroplast transgenic lines were generated by particle
bombardment as described previously. After bombarding
Nicotiana tabacum cv. Petit Havana tobacco leaves with the
chloroplast vectors, the leaves were grown on selective
medium containing 500 µg/ml spectinomycin. Three different genetic events can produce spectinomycin-resistant
tobacco shoots: (1) transgene integration into chloroplasts,
(2) into the nuclear genome or (3) spontaneous mutants.
PCR with two specific primers, 3P and 3M, allowed identification of shoots having the desired chloroplast transgene
integration. The 3P primer annealed to the native chloroplast
genome and the 3M primer annealed to the aadA gene (see
FIG. lC). Nuclear transformants were eliminated because
3P will not anneal and mutants were ruled out because 3M
will not anneal. At least 50 shoots were obtained in the initial
transformation, a high frequency which suggests that there
was no inhibitory effects of PA. Among clones tested, in both
constructs, all were chloroplast transformants. No spontaneous mutants or nuclear transformants were observed (see
FIG. lD).

The pLD-JWl Vector
FIG. 1 shows tobacco constructs and PCR confirmation of
chloroplast transgene integration. FIG. lA shows the pLDJWl vector used for chloroplast transformation. The tmI and
trnA genes were used as flanking sequences for homologous
recombination. The constitutive 16s rRNA promoter (" 16s"
in FIG. lC) was used to regulate transcription. The aadA
gene conferring spectinomycin resistance was used for
selection of transgenic shoots. The pag gene coding for
anthrax protective antigen was regulated by the psbA promoter and 5' (5UTR) and 3'UTR (T) elements. As shown in
FIG. lB, The pLD-JW2 construct was made by adding
orfl,2 from B. thuringiensis to the pLD-JWl vector. FIG. lC
shows a scheme for PCR using the primers 3P and 3M to
investigate chloroplast transgene integration. The 3P primer
anneals to the native chloroplast genome and the 3M primer
anneals to the aadA gene, generating a 1.65 kb PCR product
in chloroplast transgenic lines. FIG. lD shows the results of
an analysis of randomly selected clones. Lane 1: Ladder;
Lane 2: Negative control wild type tobacco plant DNA;
Lane 3: Positive transgenic plant DNA (pLD-5'UTR/HIS/
THR/IFNa2b ); Lane 4-8: 5 different transgenic lines tested.
The pLD-JWl vector (8.3 kb, see FIG. lA) was constructed to transform tobacco chloroplasts. This construct is
based on the vector pLD the Applicant has used successfully
in previous publications. Specifically, the construct is connected to the Applicants universal vectors, which are
described in detail in PCT patent publication WO 99/10513,
which is hereby incorporated by reference. The tmI and trnA
genes were used as flanking sequences for homologous
recombination to insert a pag-containing cassette into the
spacer region between these two tRNA genes in the inverted
repeat region of the chloroplast genome, as reported previously. It should be noted that it is possible to insert the pag
containing cassette into any of a number of spacer regions
between genes. The constitutive 16s rRNApromoter, which
can be recognized by both the chloroplast encoded RNA
polymerase and the nuclear encoded RNA polymerase, was
used to drive transcription. Any of a number of promoters
functional in plastids and well understood and known in the
art can be used to help drive transcription.
The aadA gene conferring spectinomycin resistance was
used for selection of transgenic shoots. It is noted however,
that the use other antibiotic-resistant genes or an antibiotic
free selectable marker such as BADH, could also be used in
the construction of the vector. The pag gene coding for
anthrax protective antigen was regulated by the psbA 5' and
3' elements. The 5'UTR from psbA, including its promoter,
was used for transcription and translation enhancement and
the 3'UTR region conferred transcript stability.
One skilled in the art would recognize that an alternative
chloroplast vector can be constructed without the use of any
promoter, because all polycistronic spacer regions contain a
native promoter which can be used to drive transcription.
A second construct was made by adding orfl,2 from B.
thuringiensis to the pLD-JWl vector, forming the pLD-JW2
vector (see FIG. lB). The orfl,2 gene codes for a putative
chaperone. Including the orfl,2 gene was done to test
whether the putative chaperone could fold a heterologous
Bacillus protein (i.e., PA) into cuboidal crystals or form
inclusion bodies, protect PA from proteolytic degradation,
and thereby facilitate purification.
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Chloroplast Integration of Transgenes and Homoplasmy:
Southern blots were done to further verify that the transgenes had been integrated into the chloroplast genome and
to determine homoplasmy (containing only transformed
chloroplast genomes) or heteroplasmy (containing both
transformed and untransformed chloroplast genomes). Total
plant DNA was digested with the enzyme Bg!II which
generated a 4.4-kb fragment in wild type, 5.2-kb and 3-kb
fragments in pLD-JWl transgenic lines, and 6.8-kb and 3-kb
fragments in pLD-JW2 transgenic lines when hybridized
with a 0.81-kb probe made from chloroplast flanking
sequences (see FIG. 2A-D). The blots were also hybridized
with a 0.52-kb probe made from pag coding sequence (see
FIG. 2E). All of the pLD-JW2 plants appeared to be
homoplasmic. In the pLD-JWl plants, transgenic line 2
appeared to be heteroplasmic, which is not uncommon to
find in Ta plants. Ta refers to first generation transgenic lines
and T 1 refers to second generation lines obtained by germination of seeds from Ta.
FIG. 2 shows southern blots to investigate the site of
transgene integration and determine homoplasmy or heteroplasmy. The figure shows a schematic diagram of the
expected products from digestion of wild type untransformed plant as follows: FIG. 2A shows plants transformed
with pLD-JWl; FIG. 2B shows plants transformed with
pLD-JW2. FIG. 2D shows a flanking sequence probe revealing heteroplasmy in pLD-JWl line and homoplasmy in
pLD-JW2 lines. FIG. 2E shows pag sequence probe showing
presence of pag in transgenic lines.
PA Expression in Transgenic Chloroplasts:
Western blots were performed on transgenic lines containing the two different constructs. Full length 83-kDa
polypeptide was detected on blots, confirming PA expression
in transgenic lines and absence of unique proteases that
cleave PA in plant cells (see FIGS. 3A-C). Presence of active
furin or trypsin-like proteases would have resulted in a
63-kDa protein due to cleavage at the sequence RKKR (SEQ
ID NO:l) (amino acids 164-167). The sequence FFD (SEQ
ID N0:2) at residues 312-314 is another site that is highly
sensitive to chymottypsin-like enzymes, and cleavage would
have resulted in 47- and 37-kDa fragments. No other cleaved
PA products were observed (see full length blots shown),
demonstrating stability of chloroplast derived PA. Prior to
the Applicant's discovery, it was widely believed that pro-
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teases would cleave long antigenic bacterial peptides, but
this invention illustrates that the antigenic bacterial peptides
are free from protolytic degradation.
The T 1 transgenic lines showed a greater amount of PA in
the pLD-JWl lines as compared to the pLD-JW2 lines.
Additional western blots were done comparing two different
detergents in the extraction buffers, CHAPS and SDS, and
both were found to extract PA equally well (see FIG. 3C).
The supernatant and the homogenate were also found to be
comparable suggesting that most of the PA is in the soluble
fraction. After storage for two days at 4 ° C. and -20° C., the
PA in plant crude extracts is quite stable (see FIG. 3C).
Powdered leaf was stored at -80° C. for several months
before performing western blots or functional assays; this
did not result in any noticeable decrease in PA quantity or
functionality. This facilitates long term storage of harvested
leaves before extraction of PA for vaccine production.
Native PA has been shown to be highly unstable due to
proteolysis-sensitive sites, which have been modified to
confer better stability.

PA accumulation was visualized in crude plant extracts by
Coomassie staining. When a capture ELISA was used to
quantify PA, it appeared that PA constituted a large percentage of total soluble protein in some extracts. While these
values may reflect detection of partially cleaved PA, they do
not result from non-specific interaction of the antibodies
with any other proteins, because no signal was detected in
untransformed plants. However, the data set forth herein is
from quantitative scanning of polyacrylamide gels and not
from the capture ELISA.

Quantification of PA in Transgenic Chloroplasts:
In order to quantify the amount of PA in transgenic
chloroplasts, western blots were used to observe varying
dilutions of the crude extract. PA was quantified using gel
documentation software (Bio-Rad). Based on western blot
analysis, pLD-JWl T 1 transgenic lines showed 44 µg PA/g
of fresh tissue (22 µg/ml). An average tobacco leaf weighed
6.5 g; therefore 286 µg PA could be expressed per leaf. The
pLD-JW2 transgenic lines showed lower levels of PA accumulation, probably due to interference of both UTRs, resulting in decrease in translation. We have observed recently
that the combination ofORF-psbA5'UTR decreases expression of human serum albumin in transgenic chloroplasts.
The psbA regulatory sequences, including the promoters
and UTRs, have been shown to enhance translation and
accumulation of foreign proteins under continuous light.
Therefore, pLD-JWl T 1 transgenic plants were placed in
continuous light and young, mature, and old leaves were
collected after 3 or 5 days of continuous illumination.
Western blots were performed using different dilutions of
crude plant extracts (see FIG. 4A-B). The 3 day mature and
young leaves contained 80 µg PA or 108 µg PA/g of fresh
tissue. The 5 day old, mature and young leaves contained 32
µg PA, 108 µg PA or 156 µg PA/g of fresh tissue, respectively. Thus, young leaves showed the highest accumulation
of PA and old leaves showed the lowest, probably due to
proteolytic degradation induced during senescence. These
assays quantified only full length PA. In spite of loading
500-1000 fold more protein of untransformed plant extracts,
no cross-reacting protein was observed with the monoclonal
antibody used.
FIG. 4 shows total protein from plant extracts loaded in
each lane is shown in parenthesis. FIG. 4A shows pLD-JWl
transgenic line in 3 days of continuous light, 1:20 dilutions.
Lane 1: old leaf (187 ng); Lane 2: mature leaf (369 ng); Lane
3: young leaf (594 ng); Lanes 4-5: blank; Lane 6: 10 ng PA;
Lane 7: 20 ng PA; Lane 9: ladder; Lane 10: wild type
(15,000 ng). FIG. 4B shows pLD-JWl transgenic line in 5
days of continuous light, 1:20 dilutions. Lane 1: old leaf
(214 ng); Lane 2: mature leaf (588 ng); Lane 3: young leaf
(745 ng); Lane 6: 10 ng PA; Lane 7: 20 ng PA; Lane 8: blank;
Lane 9: ladder; Lane 10: wild type (15,000 ng). FIG. 4C is
a histogram ofµg PA/g fresh tissue in young, mature, and old
leaves after 3 (blue) and 5 (red) days of continuous illumination.
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PA Functionality Determined by Macrophage Lysis:
Supernatant and homogenate samples from both T 0 constructs, pLD-JWl and pLD-JW2, were tested. Two different
buffers were used to extract proteins--one contained
CHAPS detergent and one did not have any detergent. The
PA produced in chloroplast transgenic lines was able to bind
to the anthrax toxin receptor, be cleaved to the 63-kDa
fragment, heptamerize, bind LF, be internalized and lyse the
macrophage cells. Therefore the transgenic plants were
shown to produce fully functional PA (see FIG. SA). Active
PA was found in both the supernatant and homogenate
fractions; but was quantitated only in the former. The assay
using CHAPS gave a result of the pLD-JWl supernatant
with the best yield. In the absence of any detergent, the
supernatants lysed the macrophage cells better than the
homogenates. Crude plant extracts contained up to 5 µg per
ml functional PA confirming expression of high levels of
functional PA. Supernatant samples from Tl pLD-JWl
transgenic lines were tested and they resulted in approximately 12-25 µg functional PA per ml (see FIG. SB) and the
toxicity was entirely dependent on the presence of LF.
The threat of biological warfare and terrorism is real. The
most effective way to prevent or deter effective use of
anthrax as a weapon would be to produce an efficacious and
inexpensive vaccine. Plants are an inexpensive and easy way
to produce recombinant proteins, without human or animal
pathogen contamination. Because one acre of tobacco yields
up to 40 tons of fresh leaves (40,000 kg in three cuttings),
the production could be up to 6.24 kg PA per acre based on
expression levels reported in this manuscript. There is less
than 50% loss during purification from plant extracts (loss of
foreign protein is generally between 30 and 90% ), and at 5
µg PA per dose (which is roughly equivalent to prior art
vaccine which is in a range of 1.75 to 7 µg PA), one can
produce 600 million doses of vaccine per acre of tobacco.
Thus a few acres of transgenic tobacco can meet the world's
need for the anthrax vaccine.
Experiment Protocol for Example 1
Bombardment and Selection of Transgenic Plants:
Sterile Nicotiana tabacum cv. Petit Havana tobacco
leaves were bombarded using the Bio-Rad PDS-1000/He
biolistic device as previously described. The bombarded
leaves were placed on RMOP medium containing 500 µg/ml
spectinomycin for two rounds of selection on plates and
subsequently moved to jars ofMSO medium containing 500
µg/ml spectinomycin.

60

65

PCR Analysis to Test Stable Integration:
DNA was extracted from tobacco leaves using Qiagen
DNeasy Plant Mini Kit available from Qiagen, Valencia,
Calif. PCR was performed using the Perkin Elmer Gene
Amp PCR System 2400 (available from Perkin Elmer,
Chicago, Ill.). PCR reactions contained template DNA,
lxTaq buffer, 0.5 mM dNTPs, 0.2 mM 3P primer, 0.2 mM
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3M primer, 0.05 units/µ! Taq Polymerase, and 0.5 mM
MgCl 2 . Samples were run for 30 cycles as follows: 95° C.
for 1 min, 65° C. for 1 min, and 72° C. for 2 min with a 5
min ramp up at 95° C. and a 72° C. hold for 10 min after
cycles complete. PCR products were separated on 1% agarose gels.

Macrophage Lysis Assays:
Approximately 100 mg of powdered leaf tissue was
extracted with 200 µI of extraction buffer. For the supernatant fraction, the buffer and tissue were centrifuged for 5
minutes at 10,000xg and the supernatant was placed in a
new tube. For the homogenate, it was all of the tissue and the
buffer. RAW 264.7 macrophage cells were plated in 96-well
plates in 120 µI DMEM medium and grown to 50% confluence. The medium was aspirated and replaced with 100 µI
medium containing 250 ng/ml LF. The control plate received
medium with no LF to test toxicity of plant material and
buffers. In separate 96-well plates, the plant samples were
diluted serially 2-fold and 40 µI of the dilutions were
transferred onto the RAW cells so the top row had plant
extract at 1:14 dilution. MTT (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide) was added after 5-10
hours to assess cell death. Gu, M. L., Leppla, S. H.,
Klinman, D. M. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective
antigen (Vaccine. 17, 340-344 (1999)).

Southern Blot Analysis:
Total plant DNA was digested with Bg!II and run on a
0.8% agarose gel at 50 V for 2 hours. The gel was soaked in
0.25 N HCI for 15 minutes and then rinsed 2x with water.
The gel was soaked in transfer buffer (0.4 N NaOH, 1 M
NaCl) for 20 minutes and then transferred overnight to a
nitrocellulose membrane. The membrane was rinsed twice
in 2xSSC (0.3 M NaCl, 0.03 M Sodium citrate), dried on
filter paper, and then crosslinked in the GS GeneLinker
(Stratagene, La Jolla, Calif.). The flanking sequence probe
was made by digesting pUC-CT vector DNA with BamHI
and Bg!II to generate a 0.81 kb probe. Lee, S. B., Byun, M.
0., Daniell, H. Accumulation oftrehalose within transgenic
chloroplasts confers drought tolerance. Molecular Breeding
(in press) (2002). The pag probe was made by digesting pag
with Neal to generate a 0.52 kb probe. The probes were
labeled with 32 P using the ProbeQuant G-50 Micro Colunms
(Amersham, Arlington Heights, Ill.). The probes were
hybridized with the membranes using Stratagene QUICKHYB hybridization solution and protocol (Stratagene, La
Jolla, Calif.).
Western Blot Analysis:
Approximately 100 mg ofleaftissue was ground in liquid
nitrogen with a mortar and pestle and stored at -80° C. for
several months. When it was time to extract the proteins, the
powder was removed from -80° C. and 200 µI of plant
extraction buffer was added and mixed with mechanical
pestle (0.1% SDS, lOOmMNaCI, 200mMTris-HC!pH 8.0,
0.05% Tween 20, 400 mM sucrose, 2 mM PMSF). The plant
extract was then centrifuged for 5 minutes at 1O,OOOxg to
pellet the plant material. The supernatant containing the
extracted protein was transferred to a fresh tube and an
aliquot was taken out, combined with sample loading buffer,
boiled, and then run on 8% SDS-PAGE gels for one hour at
80 V, then 2 hours at 150 V. Gels were transferred overnight
at 10 V to nitrocellulose membrane. The membrane was
blocked with PTM (lxPBS, 0.05% Tween 20, and 3% dry
milk). PA was detected with anti-PA monoclonal antibody
14B7. Secondary antibody used was goat anti-mouse IgG
conjugated to horseradish peroxidase (American Qualex
Antibodies, Al 06PN).
The stability assay utilized SDS buffer (0.1 % SDS, 100
mM NaCl, 10 mM EDTA, 200 mM Tris-HCI pH 8.0, 0.05%
Tween 20, 14 mM ~-mercaptoethanol, 400 mM sucrose, 2
mM PMSF) and CHAPS buffer (4% CHAPS, 100 mM
NaCl, 10 mM EDTA, 200 mM Tris-HCI pH 8.0, 14 mM
~-mercaptoethanol, 400 mM sucrose, 2 mM PMSF). Two
hundred µI of each buffer was added to 100 mg powdered
leaf tissue. For supernatant fractions, the extraction was
centrifuged at 10,000xg for 5 minutes and supernatant was
removed. For homogenate, the entire extract was used. The
samples were stored at 4 ° C. and -20° C. for two days. The
rest of the western protocol was the same as described
above. Dilutions of 1: 10 and 1:20 of the protein extracts
were made and run on the gel along with 20, 10, and 5 ng
of PA protein standards to generate a standard curve for
protein quantification. After the film was developed, the PA
was quantified using the Gel-Doc.
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Prior to the creation of the pTom-BADH2-G10-pag -8.8
kb vector construct (FIG. 7), the Applicant constructed the
pLD Tom-BADH vector (FIG. 6A) illustrating the ability to
transform the chloroplast genome of edible dicots. The
Tom-BADH vector was constructed to with two selectable
marker genes (BA and spectinomycin) to test ability of
transformed plants to grow on BA as compared to spectinomycin. The pLD-Tom-BADH vector contains the chimeric aadA gene and the BADH gene driven by the constitutive 16 S rRNA promoter and regulated by the 3'UTR
region of psbA gene from petunia plastid genome. In this
construct both, aadA and BADH possess the chloroplast
preferred ribosomal binding site, GGAGG. Another suitable
vector used for tomato chloroplast transformation is the
pLD-Tom-UTR-BADH vector, which has the constitutive
16 S rRNA promoter driving the expression of the dicistron,
in which the BADH is under the regulation of the promoter
and the 5'UTR of the psbA gene and the 3'UTR of psbA
gene, for enhanced expression. FIG. 6B shows the PCR of
tomato chloroplast transformed with the pLD-Tom-BADH
using 3P/3M primers. Specifically FIG. 6B shows, Lane 1
and 9-1 Kb plus Ladder; 2-mutant; 3-Clone#8;
4--Clone#9; 5-Clone#ll; 6-Wild type; 7-Positive control; 8-pLD-Tom-BADH. From results observed in the gel
in FIG. 6B, integration of transgene is quite evident.
FIGS. llAand B show the response of tomato cotyledons
transformed with the pLD-Tom-BADH vector grown on
RMOP, which is supplemented with 2.5 nm betaine aldehyde, wherein llA shows the wild type control and llB
shows the transformant.
After successful construction and integration into the
tomato chloroplast genome using the pLD Tom-BADH
vector of FIG. 6A, the Applicant then constructed the
pTom-BADH2-G10-pag -8.8 kb vector, which is illustrated
in FIG. 7. FIG. 7 shows the schematic construct of the
pTom-BADH2-G10-pag -8.8 kb vector, which was constructed containing the selectable marker gene BADH. This
construct is also be made using the aad gene to confer
spectinomycin resistance in place of the BADH gene. After
bombarding the tomato cotyledons (seed leaves or embryonic leaves) with the tomato construct of FIG. 7, the
cotyledons were put on selection media containing Betaine
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Aldeyhyde (BA) and calli formed. The calli were transferred
to new selection media to obtain shoots.
FIG. 10 shows the first selection after bombardment with
the pTom-BADH2-G10-pag -8.8 kb vector, wherein the
cotyledons were incubated in the dark for 48 hours and then
the bombarded cotyledons were cut. The RMOP medium
shown in FIG. 10 is a shoot inducing media. The bombarded
cotyledons were grown on 2.5 mM Betaine Aldehyde (BA)
for selection.
FIG. 8 shows the PCR test that was performed to determine integration of the pTom-BADH2-G10-pag -8.8 kb
vector, where the tomato shoots were tested with PCR to
confirm integration of the transgene. In FIG. 8, the + is
pTOM-GlO-PA vector control, - is WT Tomato plant, and
#3 is the transgenic tomato plant. This confirmation utilized
appropriate primers.
To apply the plastid transformation technology to edible
plants to produce an edible vaccine, a first generation tomato
vector is constructed containing pag. TrnI and trnA are
homologous recombination regions in tomato; 5'UTR from
psbA is used for translation enhancement and also contains
it's own promoter; BADH gene confers Betaine Aldehyde
(BA) resistance; GlO is a translation enhancer from the T7
bacteriophage; pag codes for the protective antigen, and T is
the psbA terminator.
The pDDll vector is cleaved with NdeI & Natl to remove
the gene and leave opened pB!ue-G 10 region of the vector.
The pB!ue-T7-pag vector is then cleaved with NdeI & Natl
to remove the pag gene -2.2 kb. The pag gene is ligated into
the opened pB!ue-G 10 vector, and the resulting pB!ue-G 10pag is cleaved with SmaI & Natl to remove the GlO-pag
-5.2 kb segment from the pB!ue-G 10-pag vector. Finally the
pTom-BADH2 vector is cleaved with SmaI and Natl, and
then the G 10-pag fragment is ligated into the vector creating
a pTOM-BADH2-G10-pag -8.8 kb (FIG. 7).

neutralization by serum antibodies following intranasal
immunization. Equivalent results were seen following transcutaneous immunization.

PCR Confirmation of Transgene Integration:
After bombarding the tomato cotyledons (seed leaves or
embryonic leaves) with the tomato construct vector, pTOMBADH2-G 10-pag -8.8 kb, the cotyledons are put on selection media containing Betaine Aldeyhyde (BA) and calli
formed (FIG. 10). The calli are transferred to new selection
media to obtain shoots. Shoots are tested with PCR to
confirm integration of the transgene, which utilizes appropriate primers (FIG. 8).
Mucosa! and Transcutaneous Immunization Against
Anthrax:
Anthrax vaccine studies focused on mucosa! and transcutaneous immunization with rPA as a vaccine antigen when
delivered in conjunction with a novel adjuvant, designated
LT(R192G). This adjuvant was shown to be effective at
augmenting protection against a variety of bacterial, viral,
and fungal pathogens when delivered with appropriate antigens intranasally, orally, rectally, or transcutaneously. This
adjuvant was developed by the Clements laboratory at
Tulane University Health Sciences Center with funding
from NIH and the Department of Defense and has been
evaluated in a number of Phase I and Phase II clinical trials.
In rPA studies, a number of immunologic outcomes were
measured, but the studies focused primarily on those associated with protection against inhaled pathogens-serum
and bronchial lavage (BAL) fluid antibodies. It was demonstrated that mucosa! and transcutaneous immunization of
mice with rPA induces high levels of antigen-specific antibodies in serum and in bronchoalveolar lavage fluids. Moreover, circulating anti-rPA antibodies are able to neutralize
the cytotoxic effect of anthrax Lethal Toxin when tested in
macrophage cytotoxicity assays. FIG. 12 shows the serum
anti-PA as determined by ELISA and the in vitro toxin
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Tomato Chloroplast Integration Vector:
Since the expression of the foreign protein is desired in
chromoplasts of tomato fruit, the gene of interest needs to be
under the control of a regulatory sequence that is free from
cellular control. In this context, examples of suitable candidate regulatory sequences are the T7 gene 10 leader
sequence and cry2Aa2 UTR. The T7 gene 10 leader
sequence is used to express foreign proteins in transgenic
chromoplasts. The cry2Aa2 UTR accumulates foreign protein in chromoplasts as efficiently as the psbA UTR. The
selectable marker for the future generation vectors can
optionally be the BADH gene under the regulation of psbA
promoter and 5'UTR as psbA is one of the most efficiently
translated chloroplast genes in green tissues. Since green
tissue is used for introducing the transgene into the chloroplasts in tomato, it is ideal to use the light regulated psbA
UTR for the selectable marker.
Tomato Seed Sterilization and Growth Conditions:
FIG. 9 shows tomato seeds (Moneymaker and Ady varieties) that are surface sterilized with ethanol for 30 s,
followed by a 20 min treatment with 1.5% NaOCI and 0.1 %
Tween 20. Seeds are washed thoroughly with sterile water
(at least 3-4 times) and transferred to germination media
(FIG. 14). Germination media consists of MS salts with 30%
sucrose and 0.8% agar. About 20 seeds are inoculated per
bottle and placed under a photoperiod of 16 h light and 8 h
dark for 8-10 days to obtain cotyledons for particle bombardment. The cotyledons are then excised either as an
explant for bombardment or the resulting seedlings are used
for transplantation to obtain leaves.
The cotyledons and leaf material are bombarded using the
particle gun. After bombardment the explants are then
incubated in the dark for 48 h. The cotyledons and leaves are
then cut into small pieces and placed onto RMOP media
supplemented with 2.5, 5.0 and 7.5 mM ofbetaine aldehyde
for regeneration. In the case of cotyledons, the concentration
of 2.5 nm BA is optimal, but not required, as regeneration of
putative transformants could be observed after two weeks.
Specifically, there is no response on media having higher
concentrations of 5.0 and 7.5 mM BA. With leaves, the
concentration of 1 and 1.5 mM is optimal for pLD-TomBADH and pLD-Tom-UTR-BADH respectively.
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Preparation and Analysis of Stable Tomato Plant Transformants:
Selection is optimally performed in the presence of BA,
but has also been performed in the presence of antibiotics.
After selection, PCR analysis is performed as described
above, as is well understood in the art. Finally Southern and
northern blot analyses are performed as described above,
and well understood in the art, to determine the amount and
level of transformation in the chloroplast genome.
Example 3
Transformation of Carrot to Produce Anthrax
Vaccine
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Carrot (Daucus carota L.) is a biennial plant grown for its
edible taproot. It is one of the most important vegetables
used worldwide for human consumption. Carrot taproots are
rich in vitamin A and fiber and are ideal to genetically
manipulate in the chromoplast for the production of edible
vaccines. For transformation of carrot, flanking sequences
(trnI and tmA) are amplified with the help of PCR. Duration
for regeneration of carrot plantlets is shortened to four
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months from eight months when replacing the antibiotic
selection with BA. The same chloroplast constructs as
described above for tomatoes are used for carrot except that
homologous recombination regions i.e. tml and trnA are
derived from carrot chloroplast DNA. The advantage of
using carrot is that from small clusters of cells or a small
piece of carrot one can get thousands of transgenic plants in
a limited space. Moreover, single cells are directly in contact
with the culture media surface. Therefore, even a small
quantity of selecting agent (betaine aldehyde) is more effective in comparison to other larger tissues. Carrot is easy to
store for long periods of time.

from Fl gene (513 bp/15.5 kDa) and the entire V antigen
(980 bp/35 kDa). The entire immunogenic sequence will be
(441 +980 +6 for a hinge= 143 7 bp ). With the protein of 478
amino acids having a calculated mass of 53,193 and a pl of
5.1 has shown this fusion protein to be immunoprotective.
Fl-V was modified to add an EcoRl site. This fragment
is cloned into the universal chloroplast vector, which has
been described above, with the psbA 5'UTR upstream of the
Fl-V fusion. The use of the psbA 5'UTR, is not required, but
it has been shown to increase expression of foreign proteins
by chloroplast.
Large-scale expression of the fusion protein results in the
formation of inclusion bodies as observed with several other
foreign proteins expressed in transgenic chloroplasts. These
inclusion bodies are easily separated by centrifugation.
Another option is use of ammonium sulphate for the precipitation of the protein.
Optionally, a His-tag with an enterokinase cut site was
added to the above construct. The His-tag allows for purification on a nickel colunm with subsequent cleavage of the
fusion protein from the His-tag.
The plasmid pPW731 (a pET-24 vector) carrying the gene
for the F 1V fusion protein was delivered in BLR strain of E.
coli. Because of the exonuclease activity in BLR, XLl-Blue
strain of E.coli was transformed with pPW731. Using Ndel
and Natl, FlV was cut out of pPW731 and ligated into
PCR2.1 with 5' psbA. In order to ligate 5' psbA-Fl V into the
universal chloroplast vector, pLD-CtV, PCR2.l-5' psbAFlV was cut with Sad, and blunt ended, then cut with Natl.
This was ligated into pLD-CtV which had been cut with
EcoRV (blunt end) and Natl. This produced the chloroplast
vector pLDS-FlV containing the 5'UTR psbA upstream of
FlV, which was then used for bombardment. The use of the
psbA 5'UTR has proven to increase expression of foreign
proteins by chloroplasts.
FIG. 13A shows the construct of the pLDS-Fl V vector,
wherein the vector contains the FIN antigen gene contained
in the spacer region between the tml and tmA genes. It
should be understood that the FIN antigen gene could be
inserted into any of a number of spacer regions between
chloroplast genes, which are described and illustrated in
Sugita, M. Sugiura, M. Regulation of gene expression in
chloroplast of higher plants, Plant Molecular Biology
32:315-326, 1996).
FIG. 13B shows PCR restriction enzyme analysis of
pLDS-FlV withXhoI, EcoRI, and Ndel, which showed that
the psbA-FlV sequence to be in proper orientation in pLD.
(Xhol yielding: 340 bp, 2679 bp, and 4634 bp: EcoRI
yielding 682 bp, and 6953 bp: and XhoI/NdeI yielding 340
bp, 925 bp, 1102 bp, 1620 bp, 3610 bp, and incomplete
digestion at 2601 bp, and 4550 bp ). Lane 1: 1 KB Ladder,
Lane 2: pLDS 37C, Lane 3: pLDS 4C, Lane 4: EcoRI, Lane
5: Xhol, Lane 6: XhoI/NdeI (overnight), Lane 7: XhoI/NdeI.
The sequencing of pLDS-(5' psbA)-FlV using the 5'UTR
primer, which lands on the 5' psbA, showed no changes
during vector construction.
FIGS. 14A and 14B show PCR confirmation oftransgene
integration into the chloroplast genome.
After bombarding tobacco leaves with pLDS-FlV, there
are three possibilities that might produce shoots: chloroplast
transgenic, nuclear transgenic, and mutants resistant to spectinomycin. In order to select chloroplast transgenic plants
we utilize two PCR reactions. The first (FIG. 14A), which
checks for chloroplast intergration, uses 3P and 3M primers
which land on the native chloroplast geneome and the aadA
gene, respectively. Nuclear transformants are screened out
because 3P will not anneal. Mutants are screened out

Plant Material and Tissue Culture:
Seeds of carrot (Daucus carota L. cv Nantaise) are sown
in pots and placed under a growth chamber with appropriate
growth conditions for as little as four weeks to as long as a
year. The hypocotyls are then cut into segments of 1 cm long
and placed either on semi-solid callus induction medium or
in 50 ml MS medium containing 3% sucrose, 0.1 mg/I
2,4-dichlorophenoxyacetic acid (2,4-D) having pH 5.7.
After 3 weeks of continuous shaking at 24 ° C. and 120 rpm,
liberated cells are collected on a 100 µM mesh, centrifuged
(150xg for lo min) and resuspended in fresh medium.
Rapidly growing cell cultures can be subcultured weekly.
Next, callus formation from hypocotyls segments is established on semi-solid MS medium (Carolina Biological supply company) containing 1 mg/I kinetin and 3 mg/I 2,4-D.
Homogenously growing calli is subcultured every 4 weeks
on fresh medium. The resulting friable calli is then resuspended in 50 ml MS medium containing 3% sucrose and 0.1
mg/kinetin. Finally, suspension-cultured cells are filtered
through a 100 µM mesh and subjected to bombardment with
chloroplast vectors.
Bombardment and Regeneration of Carrot Chromoplast
Transgenic Plants:
Fine cell suspension culture of carrot, evenly spread over
MS semi-solid medium is used for bomardment. After
bombardment the explants are incubated in the dark for 48
hand later in appropriate light condition (16/8 h day/night
cycle at 24° C.). Somatic embryogenesis is induced in a
suspension of single cells and small clusters harvested on
sieve and low-speed centrifugation. The harvested cells are
washed once with hormone free liquid MS medium and
resuspended in 40 ml hormone free MS medium containing
different concentrations ofbetaine aldehyde (1.5, 2.5 and 3.5
mM). Transgenic somatic embryos, visible 2 weeks after
induction, are selected manually and transferred onto plates
with semi-solid MS medium containing 1.5% sucrose and
variable concentrations ofbetaine aldehyde (1.5, 2.5 and 3.5
mM). The plates are sealed with parafilm. After two weeks,
somatic embryos development into plantlets which are transferred to soil in pots. Initially, the pots are covered with
plastic bags to maintain high humidity and irrigated with
progressively reduced concentrations of MS salts for the first
week, followed by tap water in the second week. Transgenic
plants with stable expression of recombinant protein are then
utilized for suitable assays.
Example 4
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Construction for the Fl V Fusion Protein (the
Plague Antigen)
The production of Yersinia pestis vaccine in a low nicotine strain of tobacco (LAMD) is accomplished by expressing in chloroplasts the F 1-V antigen fusion protein produced
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because 3M will not anneal. Positive chloroplast transformants produce a 1.65 Kb PCR product.
The second PCR reaction (FIG. 14B) uses SP which lands
on the aadA gene and 2M which lands on trnA. This
produces a PCR product of 1.65 kb+Insert (psbA=203
bp+Fl V=l437 bp )=3.29 Kb. Plants 2-5, 8, and 10 clearly
contain the transgene.
FIG. 15A shows the western blot of pLDS-FlV from
XLl-Blue strain of E. coli, and 15B shows the western blot
of plants 1 and 2.
Turning to FIG. 15A showing the Western blot of FlV
expression in E. coli, the expression in E.coli was detected
by rabbit anti-Fl as the primary antibody and alkaline
phosphatase labeled goat anti-rabbit IgG as the Western blot
of Fl V expression in E. coli was detected by rabbit anti-Fl
as the primary antibody and alkaline phosphatase labeled
goat anti-rabbit IgG as the secondary antibody. Specifically
the western blot in FIG. 15A shows: Lane 1: pLDS-FlV;
Lane 2: Flantigen; Lane 3: V antigen; Lane 4: FlV fusion
protein.
FIG. 15B illustrates the Western blot of Fl V expression in
plants as was detected by rabbit anti-Fl and anti-V as
primary antibodies and alkaline phosphatase labeled goat
anti-rabbit IgG as the secondary antibody. Controls and
samples were boiled. Specifically the western blot in FIG.
15B shows: Lane 1: purified FlV fusion protein; Lane 2:
Untransformed Petit Havana; Lane 3: Transformed plant line
#1; Lane 4: Transformed plant line #2. From this western
blot it is clear that transbgenic line 2 has surpassed line 1 in
growth and is very healthy confirming that the foreign
protein is not toxic to plants.

proteins. Spontaneously forming CTB pentamers exhibit
intact transcytosis to the external basolateral membrane of
intestinal epithelium, and have been widely used as oral
vaccine vehicles.

Cloning Fl-V Antigen into Tomato:
The Fl-V antigen, which is a bacterial antigen, was
cloned into the tomato pLD vector between gene 10 and rps
16 terminator. This was discussed further above. In this case,
the selectable marker, BADH, with psbA 5'UTR and psbA 3'
follows the rpsl6 region. The second vector made contains
Fl-V attached to the carboxy terminus ofCTB. CTB serves
as a mucosa! carrier for this plague protein.

Example 6
Double Barrel Plastid Vectors
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Example 5
Oral Delivery of Recombinant Proteins via Cholera
Toxin B Subunit (CTB)
The increased production of an efficient transmucosal
carrier molecule and delivery system in chloroplasts of
plants allows the production of plant based oral vaccines and
fusion proteins with CTB. CTB has previously been
expressed in nuclear transgenic plants at levels of 0.01
(leaves) to 0.3% (tubers) of the total soluble protein. To
increase expression levels, the chloroplast genome was
engineered to express the CTB gene. We observed expression of oligomeric CTB at levels of 4-5% of total soluble
plant protein. PCR and Southern Blot analyses confirmed
stable integration of the CTB gene into the chloroplast
genome. Western blot analysis showed that transgenic chloroplast expressed CTB was antigenically identical to commercially available purified CTB antigen. Also, GMl-ganglioside binding assays confirm that chloroplast synthesized
CTB binds to the intestinal membrane receptor of cholera
toxin Transgenic tobacco plants were morphologically indistinguishable from untransformed plants and the introduced
gene was found to be stably inherited in the subsequent
generation as confirmed by PCR and Southern blot analyses.
Thus chloroplasts form disulfide bridges to assemble foreign
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Chloroplast transformation has been accomplished only
in a few Solanaceous crops so far. There are several challenges in extending this technology to other crops. So far,
only green chloroplasts have been transformed in which the
leaf has been used as the explant. However, for many crops,
including monocots, cultured non-green cells or other nongreen plant parts are used as explants. These non-green
tissues contain proplastids instead of chloroplasts, in which
gene expression and gene regulation systems are quite
different. During transformation, transformed proplastids
should develop into mature chloroplasts and transformed
cells should survive the selection process during all stages of
development. Therefore, the major challenge is to provide
chloroplasts the ability to survive selection in the light and
the dark, at different developmental stages. This is absolutely critical because only one or two chloroplasts are
transformed in a plant cell and these plastids should have the
ability to survive the selection pressure, multiply and establish themselves while all other untransformed plastids are
eliminated in the selection process. The Double Barrel
Plastid Vectors accomplish this by using genes coding for
two different enzymes capable of detoxifying the same
selectable marker (or spectrum of selectable markers),
driven by regulatory signals that are functional in proplastids
as well as in mature chloroplasts.
The plastid vector described here is one among several
such examples (non-limiting example). The chloroplast
flanking sequence contains appropriate coding sequences
and a spacer region into which the transgene cassette is
inserted. Any spacer sequence within the plastid genome
could be targeted for transgene integration, including transcribed and transcriptionally silent spacer regions. Both
aphA-6 and aphA-2 (nptII) genes code for enzymes that
belong to the aminoglycoside phosphotransferase family but
they originate from different prokaryotic organisms.
Because of prokaryotic nature of the chloroplast genome,
these genes are ideal for use in transgenic chloroplasts
without any codon optimization. Genes of prokaryotic origin
have been expressed at very high levels in transgenic
chloroplasts (up to 47% of total soluble protein, DeCosa et
al., 2001). Both enzymes have similar catalytic activity but
the aphA-6 gene product has an extended ability to detoxify
kanamycin and provides a wider spectrum of aminoglycoside detoxification, including amikacin. The advantage of
choosing kanamycin as a selectable marker is that it has no
natural resistance, unlike spectinomycin resistance observed
in most monocots or spontaneous point mutation of the 16
S rRNA gene observed during the selection process. In
addition, kanamycin is not in human clinical use as an
antibiotic and several crops containing kanamycin resistant
nuclear transgenes have been already approved by FDA for
human consumption (e.g. flavor savor tomatoes) and currently in the market place.
As shown in FIG. 24, in this non-limiting example, all
transgenes are regulated by the plastid Prrn promoter; this
l 6S rRNA promoter drives the entire rRNA operon in the
native chloroplast genome and contains binding sites for
both the nuclear encoded and plastid encoded RNA poly-
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merases. Therefore, this promoter is capable of functioning
in both proplastids and chloroplasts (green and non-green, in
the light and dark). The aphA-6 gene is further regulated by
the gene 10 5'UTR capable of efficient translation in the
dark, in proplastids present in non-green tissues (see GFP
expression in proplastids of non-green cells of corn and
carrot in FIGS. 19 and 23 regulated by the 16S rRNA
promoter and gene 10 UTR). The rps16 3'UTR has been
used to stabilize aphA-6 gene transcripts. The aphA-2 (nptII)
gene, on the other hand is regulated by the psbA promoter,
5' and 3' UTRs, which are light regulated and highly efficient
in the light, in chloroplasts (see A. Fernandez-San Millan, A.
Mingeo-Castel, M. Miller and H. Daniell, 2003, A chloroplast transgenic approach to hyper-express and purify
Human Serum Albumin, a protein highly susceptible to
proteolytic degradation. Plant Biotechnology Journal, in
press; also see WO 01/72959). Therefore, a combination of
both aphA-6 and aphA-2 genes, driven by regulatory signals
in the light and in the dark in both proplastids and chloroplasts, provides continuous protection for transformed plastids/chloroplasts around the clock from the selectable agent.
The gene(s) of interest with appropriate regulatory signals
(gene X) are inserted downstream or upstream of the double
barrel selectable system. Because multiple genes are
inserted within spacer regions (DeCosa et al 2001, Daniell
& Dhingra, 2002), the number of transgenes inserted does
not pose problems in transcription, transcript processing or
translation of operons (WO 01/64024). In a variation of this
example, aphA-6 and aphA-2 genes, coupled with different
transgenes are inserted at different spacer regions within the
same chloroplast genome using appropriate flanking
sequences and introduced via co-transformation of both
vectors.

Particle Bombardment of Embryogenic Calli
Micro projectiles were coated with DNA (pDA34-ZMgfp-BADH and pDA33-ZM-aadA-BADH) and bombardment was carried out with the biolistic device PDSlOOO/He
(Bio-Rad).
Prior to bombardment, embryogenic calli were selected,
transferred over sterile filter paper (Watman No. 1), and
placed on the surface of a fresh medium in standard Petrti
plates (100x15 mm). Gold particles (0.6 µm) were then
coated with plasmid DNA as follows: 50 µI of washed gold
particles were mixed with 10 µI DNA (1 µg/µl), 50 µI of
2.5M CaCl 2 , 20 µI of O.lM spermidine and vortexed.
Particles were cneterfuged for a few seconds at 3000 rpm
and then the ethanol was poured off. Ethanol washing was
repeated five times, then the pellet was resuspended in 30 µI
of 100% ethanol and placed on ice until it was used for
bombardment (the coated particles were used within 2
hours). Bombardment was carried out with the biolistic
device PDSlOOO/He (Bio Rad) by loading the target sample
at level 2 in the sample chamber under a partial vacuum (28
inches Hg).
The callus cultures were bombarded with the maize
chloroplast transformation vectors using 1100 psi rupture
discs. Following bombardment, the explants were transferred to a fresh medium; plates were sealed with micropore
tape and incubated in darkness at 25-28° C.
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Example 7
Genetic Engineering of the Corn and Ryegrass
Chloroplast Genomes
A. Transformation of Corn Chloroplast Genome
For genetic engineering of the corn chloroplast genome,
corn specific sequences, flanking the targeted integration site
in the corn chloroplast genome (trnI and trnA) were amplified with specific PCR primers and subcloned to flank the
betaine aldehyde dehydrogenase (BADH) selectable marker,
and green fluorescent protein (GFP) reporter gene expression cassette.
Callus cultures were initiated from aseptically excised
immature zygotic embryos (1-2 mm in length), produced on
self-pollinated ears of Hill (Fl) maize plants. Ears were
surface sterilized in a solution containing 2.6% Sodium
hypochlorite (prepared with commercial bleach) containing
0.1%Tween20 (polyoxyethylene sorbitan monolaurate) for
20 miniutes under continuous shaking, then rinsed 4 times in
sterile distilled water. The Embryos were then placed on the
callus induction medium CI-1, which contained N6 salts and
vitamins (463.0 mg/I (NH4 ) 2 S04 , 2830.0 mg/IKN0 3 , 400
mg/I KH 2 P04 , 166.0 mg/I CaCl 2 , 185 mg/I MgS04 .7H 2 0,
37.3 mg/I Na2 -EDTA, 27.85 mg/I FeS04 .7H 2 0, 1.6 mg/I
H 3 B03 , 4.4 mg/I MnS04 .H 2 0, 0.8, KI, 1.5 mg/I
ZnS04 .7H 2 0), 2% sucrose and 1.0 mg/I 2,4- (2,4 dichlorophenoxy acetic acid), with the rounded scutellar side
exposed and the flat plumule-radicle axis side in contact
with the medium. Callus cultures were maintained in darkness at 25-28° C. and subcultured every two weeks.
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Selection
Selection was intiated two days after bombardment. The
bombarded calli were transferred to callus induction
medium containing 5-20 mM BA (betaine aldehyde) or
25-100 mg/I streptomycin. Selection was also carried out
using 50-150 mM NaCl in combination with the BA to
maintain osmostic pressure.
Regeneration
Regeneration was initiated 6 to 8 weeks after bombardment by transferring the calli to a medium Rl containing Ms
salts and vitamins supplemented with 1.0 mg/I NAA
(a-naphthalene acetic acid), 2% sucrose, 2 g/l myoinositol
and 0.3% phytagel at pH 5.8. Regenerated plants were
transferred to R2 containing 1h MS salts and vitamins, 3%
sucrose and 0.3% phytagel at pH 5.8. Regenerated plants
were maintained in light (16/8 hr photoperiod).
Shoot Multiplication
The Surface Steriliztion and Germination of Corn Seeds
Corn seeds were surface sterilized in a solution containg
2.6% Sodium hypochlorite (prepared from commercial
bleach) containing 0.1 % Tween 20 for 20 minutes under
continuos shaking, then rinsed four times in sterile distilled
water. Seeds were grown on MS medium at pH 5.8 in
darkness. Nodal sections were excised aseptically from three
day old seedlings. The nodal sections appear as clear demarcations on the germinated seedlings and represent the seventh node. When excised, the nodal cross sections are 1.3 to
1.5 mm in length.
Particle Bombardment of Nodal Sections
Prior to bombardment, 20-30 nodal sections were placed
in the center of each petri plate with acropitila end up.
Bombardment was carried out with the maize chloroplast
vectors, using 1100, 1300 and 1550 psi rupture discs.
Multiple Shoot Induction and Selection
Nodal section explants are placed acropital end up on
shoot multiplication medium SM! composed of Ms salts and
vitamins, 1.0 mg/I 6BA (6-Benzyl amino purine), 3%
sucrose and 5 g/l phytagel at pH 5.8 under continuous light
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at 25° C. Initiation of the shoot-tip clumps from the original
shoot tips occurred 2 to 4 weeks after culture. Two days after
bombardment, transformed nodal sections were transferred
to shoot multiplicaton medium containing 5-20 mM BA or
50-100 mg/I streptomycin selective agents. Subsequent subcultures at two week intervals were carried out by selecting,
dividing and subculturing green clumps on selective shoot
multiplication medium containing 5-20 mM BA or 25-100
mg/I streptomycin.

genome, it is preferred to use the light regulated psbA
promoter/UTR or 16 S rRNA promoter/gene 10 UTR,
respectively.
B. Ryegrass Chloroplast Transformation
Annual ryegrass chloroplast transformation vector facilitates the integration of transgene into the inverted repeat
(IR) region of the annual ryegrass chloroplast genome. The
vector pLD-Ryegrass-BADH contains the chimeric aadA
gene and the BADH gene driven by the constitutive 16 S
rRNA promoter and regulated by the 3'UTR region of psbA
gene from petunia plastid genome. In this construct both,
aadA and BADH possess the chloroplast preferred ribosomal binding site, GGAGG. Another vector used for ryegrass
chloroplast transformation pLD-ryegrass-UTR-BADH has
the constitutive 16 S rRNA promoter driving the expression
of the dicistron, but BADH is under the regulation of the
promoter and the 5'UTR of the psbA gene and the 3'UTR of
psbA gene, for enhanced expression. When green tissue or
non-green embryogenic calli are used for introducing the
transgene into the com chloroplast genome, it is preferred to
use the light regulated psbA promoter/UTR or 16 S rRNA
promoter/gene 10 UTR, respectively.
Vectors for Production of Edible Anthrax Vaccine in
Transgenic Chloroplast of Com or Ryegrass:
Studies have confirmed the role of PA as the major
protective antigen in the humoral response but also indicate
a significant contribution of LF and EF to immunoprotection. The LF amino terminal domain, amino acid residues
1-254 (27 kDa) contains all the information necessary for
binding PA and mediating translocation, and this domain
alone is nontoxic because the catalytic domain of LF,
residues 255-776, is responsible for lethality. Titers of
antibody to both PA and LF from mice immunized with the
combination were 4 to 5 times greater than titers from mice
immunized with either alone. Therefore we express the
constructs LF27-PA63 (PA63 is the cleaved active form of
PA), CTB-LF27 fusion proteins, and LF27 and PA independently within the same edible plant as a standard. The
LF27-PA63 and CTB-LF27 constructs are expressed alone
and together as an operon in corn and ryegrass. It has been
demonstrated that Rotavirus enterotoxin proteins fused with
CTB is processed via the MHC II pathway generating a
strong T-cell response. Thus CTB-fusion proteins produced
in plants are ideal for oral delivery. By expressing the
CTB-LF27 and PA-LF27 we maximize immunity to lethal
toxin challenge. This is because both Gml ganglioside and
anthrax toxin receptor (ATR) can be bound by ligands and
work synergistically for maximum immune response. A
flexible hinge was introduced between fusion proteins to
reduce steric hindrance. Specifically a glycine-proline-glycine-proline hinge between CTB-LF27 and proline-glycineproline-glycine hinge between LF27-PA63 was used. The
application of less frequently used codons in plants within
the hinge peptide promotes translational arrest during the
protein elongation process, facilitating subunit folding prior
to translation. The efficiency of folding of some proteins is
increased by controlled rates of translation in vivo.
Chloroplast Transformation Protocol for Com and
Ryegrass:
Using either immature embryos (IEs) or embryogenic
callus derived from IEs as a target for biolistic gene transfer
is a well-established procedure for stable integration into the
nuclear genome of com or ryegrass. For biolistic transfer of
integrative chloroplast expression vectors, the gene transfer
protocol is adjusted and smaller particle sizes (0.6 µm
diameter) are used. Microprojectiles are coated with plasmid
DNA (chloroplast vectors) and bombardments are carried

Regeneration
The Multiple shoot clumps were regenerated by transferring them to regeneration medium Ml containing MS salts
and Vitamins, 5 mg/I IBA and 3% sucrose at pH 5.8. The
developed shoots were regenerated by transferring the shoot
tip clumps to M2 medium containing 1h MS salts and
vitamins, 3% sucrose and 3 g/l phytagel at pH 5.8. It should
be further mated that all the regeneration media are supplemented with 5-20 mM BA or 25-100 mg/I streptomycin as
the selective agents.
To engineer the com chloroplast genome free of antibiotic
resistance genes, maize calli were bombarded with a chloroplast expression vector containing the green fluorescent
protein (GFP) and the betaine adehyde dehydrogenase
(BADH) genes as selectable or screenable markers. To
compare the betaine aldehyde (BA) selection with streptomycin, another chloroplast expression vector was constructed containing the aada and the BADH genes. The
number of putative transgenic events was higher on BA
selection than on streptomycin. Transgenic com tissues
screened on BA were examined using a laser-scanning
confocal microscope. The GFP fluorescence was observed
throughout the somatic embryos of corn. Chloroplast transformation of com provides a suitable avenue for the production of edible vaccines and oral delivery of biopharmaceuticals.
Com Chloroplast Transformation Vector
Corn chloroplast transformation vector facilitates the integration of transgene into the inverted repeat (IR) region of
the corn chloroplast genome. The vector pLD-Com-BADH
contains the chimeric aadA gene and the BADH gene driven
by the constitutive 16 S rRNA promoter and regulated by the
3'UTR region of psbA gene from petunia plastid genome. In
this construct both, aadA and BADH possess the chloroplast
preferred ribosomal binding site, GGAGG. Another vector
used for com chloroplast transformation pLD-corn-UTRBADH has the constitutive 16 S rRNA promoter driving the
expression of the dicistron, but BADH is under the regulation of the promoter and the 5'UTR of the psbA gene and the
3'UTR of psbA gene, for enhanced expression. Since the
expression of the foreign protein is desired in chromoplasts
of corn seeds, the gene of interest needs to be under the
control of a regulatory sequence that is free from cellular
control. In this context, examples of suitable candidate
regulatory sequences are the T7 gene 10-leader sequence
and cry2Aa2 UTR. The T7 gene 10-leader sequence is used
to express foreign proteins in transgenic chromoplasts. The
cry2Aa2 UTR has been shown by the inventor to accumulate
as much foreign protein in chromoplasts as efficient as the
psbA UTR in green tissues. Therefore the selectable marker
for additional vectors use the BADH gene under the regulation of psbA promoter and 5'UTR, as psbA is one of the
most efficiently translated chloroplast genes in green tissues.
When green tissue or non-green embryogenic calli are used
for introducing the transgene into the com chloroplast

10

15

20

25

30

35

40

45

50

55

60

65

US 7,354,760 B2

25

26

out with the biolistic device PDSlOOO/He (Bio-Rad) as is
well-known in the art relating to the use of the "gene-gun."
Expression levels from chloroplast regulatory sequences and
the size of the proplastids are limiting factors for the
successful chloroplast transformation using non-green,
embryogenic callus tissues as a target for the gene transfer.
Therefore, it is most desirable, when using the present
invention with plant species not tested here, to compare
green shoot meristematic cultures with non-green embryogenic callus as target tissue for chloroplast transformation.
Protocols for the establishment of these tissue types are
reported for com and the grasses and are established in the
Alpeters laboratory at University of Florida at Gainesville
for ryegrass.
The timing of gene transfer after culture initiation and the
duration and level of selection affect transgenic events while
reducing the number of chimeric plants and achieving
homoplasmy and are best evaluated empirically. BADH and
aadA selectable markers are compared with the corresponding selective agents. Selection is to be maintained during the
regeneration process of plants. Regenerated plants are then
analyzed by PCR and Southern blot for integration in the
corn or ryegrass plastome.
PCR is done using DNA isolated from control and transgenic plants in order to distinguish a) true chloroplast
transformants from mutants and b) chloroplast transformants from nuclear transformants. In order to test chloroplast integration of the transgenes, the 3' primer will anneal
to the selectable marker gene while the 5' primer will anneal
to the native chloroplast genome. No PCR product is
expected with nuclear transgenic plants or mutants using this
set of primers. This screening is essential to eliminate
mutants and nuclear transformants. Total DNA from wildtype and transgenic plants is isolated and used as a template
for PCR reactions. Southern blots allow one skilled in the art
to determine the copy number of the introduced foreign gene
per cell as well as to test homoplasmy. There are several
thousand copies of the chloroplast genome present in each
plant cell. When foreign genes are inserted into the chloroplast genome, not all chloroplasts will integrate foreign
DNA resulting in heteroplasmy. To ensure that only the
transformed genome exists in transgenic plants (homoplasmy ), the selection process is continued. In order to
confirm homoplasmy at the end of the selection cycle, total
DNA from transgenic plants is probed with the chloroplast
border (flanking) sequences (the trnI-tmA fragment). Wild
type fragment size is observed along with the larger fragments of transformed plastomes. Presence of a large fragment (due to insertion of foreign genes within the flanking
sequences) and absence of the native small fragment confirms homoplasmy. The copy number of the integrated gene
is determined by establishing homoplasmy for the transgenic
chloroplast genome.
Generate Transgenic Ryegrass and Com Plants Expressing an Edible Anthrax Vaccine and Characterize Transgene
Integration and Expression
Using the aforementioned transformation protocols, vectors for the production of an orally administrable form of PA
are introduced in ryegrass and com plants. Site specific
vector integration into the ryegrass or corn plastome is then
confirmed by PCR and Southern blot analysis as specified.
Western blot verification of PA verifies that recombinant
anthrax protective antigen proteins are antigenically similar
to native PA using monoclonal antibodies against PA (Advanced ImmunoChemical GI-Bal). PA is quantified by a
ELISA using purified PA antigen as standard and commercially available antibody. Electron microscopy is next car-

ried out in mature leaves of chloroplast or mature seeds
amyloplasts of transgenic plants to detect inclusion bodies
according a protocol and similar to several published electron micrographs of transgenic chloroplasts, with immunogold label of foreign proteins. The PA protein is then
purified using a two step protocol, such as that described in
Ahuja, N., Kumar, P., & Bhatnagar, R. (2001), Rapid Purification of Recombinant Anthrax-Protective Antigen under
Nondenaturing Conditions, Biochemical and Biophysical
Research Communications, 286, 6-11. The protein is purified on AKTA-FPLC using anion exchange Resource Q
colurmi (Pharmacia). The protein is then eluted from the
colurmi with a 20 ml decreasing gradient of annnonium
sulphate. Fractions of 1 ml each are collected, analyzed on
SDS-PAGE, and those containing PA are pooled. With an
affinity tag, the PA protein can optionally be purified using
metal-chelate affinity chromatography under denaturing
conditions. Ten ml of each fraction is then analyzed on 12%
SDS-PAGE. Fractions containing the protein are collected,
pooled, and dialyzed against 10 mM Hepes buffer containing
50 mM NaCl and stored frozen at - 70° C. in suitable
aliquots.
Recombinant PA proteins are then assayed for their functional activity in the J774Al (American Type Culture Collection) macrophage lysis assay. Varying concentrations of
PA protein along with LF (1 mg/ml) are added to the cells.
The native PA along with LF is kept as the positive control.
After 3 h, cell viability is determined using the MTT
(3-(4,5-dimethyl thiazol-2-yl),-5-diphenyltetrazolium bromide) dye and the resulting precipitate is dissolved in a
buffer containing 0.5% (w/v) sodium dodecyl sulfate, 25
mM HCl in 90% isopropyl alcohol. Absorption at 540 nm is
measured and percent viability determined.
PA can be tested for susceptibility to cleavage by trypsin.
To do so, the PA protein (1.0 mg/ml) is incubated with
trypsin (1 ng/mg of protein) for 30 min at room temperature
in 25 mM Hepes, 1 mM CaC12, 0.5 mM EDTA, pH 7.5. The
digestion reaction is stopped by adding PMSF to a concentration of 1 mM. Trypsin nicked PA (1.0 mg/ml) is incubated
with LF (1.0 mg/ml) and in 25 mM Tris, pH 9.0, containing
2 mg/ml CHAPS (3-{ (3-cholamidopropyl) dimethyl ammonia }-propanesulfonic acid) for 15 min at room temperature.
Samples are applied to nondenaturing 4.5% polyacrylamide
gel.
The binding of PA protein to cell surface receptor is
analyzed in 24 well plates using constant amount of radioiodinated native PA (0.1 mg/ml). J774A.1 (ATCC) cells are
washed twice with cold HBSS for 5 minutes each time and
then placed on ice. The medium is replaced with cold
binding medium (DMEM, Dulbecco's Modified Eagle
Medium, without sodium bicarbonate containing 1% bovine
serum albumin and 25 mM, Hepes, pH 7.4). The cells are
incubated with 0.1 mg/ml of iodinated PA and varying
concentrations of the recombinant PA protein at 4° C. for 3
h and then washed with cold HBSS. The cells are then
dissolved in 0.1 N NaOH and radioactivity measured in
Gamma counter.
Leaves from transgenic lines producing epitope tagged
products are frozen and powdered at 4 ° C. using a microdismembranator and proteins are extracted in PBS with 1%
Triton X-100. Fusion proteins are purified by affinity chromatography on a nickel-agarose bed, using standard 6-His
methods, as described above.
Assessment of Immunogenic Properties of Transgenic
Plant-derived PA:
Com and ryegrass expressing PA as potential edible
vaccines against anthrax are characterized using the protocol
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described above. These are then evaluated for the ability of
PA-expressing com seeds or corn or ryegrass leaves or bay
to function as edible vaccines for the induction of serum and
mucosa! (bronchial lavage, nasal, vaginal, and fecal) antibodies by ELISA. Antibodies induced by feeding the transgenie com or ryegrass to mammals neutralize the biologic
activity of anthrax lethal toxin. This activity can be confirmed in an in vitro macrophage cytotoxicity assay. Antibody responses in mice and humans following ingestion of
transgenic potatoes and com expressing recombinant bacterial proteins have been successfully demonstrated.
Oral immunization of mice and other manmials by feeding transgenic plants or plant parts is accomplished as
follows. In the case of com and ryegrass, female BALB/c
mice are fed transgenic com or ryegrass, control corn or
ryegrass, or soluble rPA in conjunction with the mucosa!
adjuvant LT(R192G). The amount of rPA fed to control
animals is based upon the amount of PA in the transgenic
corn or ryegrass fed to the animals. That amount correlates
with the amount of transgenic com or ryegrass a mouse will
consume in a one hour period. Mice tend to eat grass if a
small amount of vanilla extract is placed on each leaf. Two
additional groups can be included in which the mucosa!
adjuvant LT(Rl 92G) is administered in conjunction with the
transgenic or control corn or ryegrass. Edible vaccines
administered to mice often require the presence of a mucosa!
adjuvant due to the small amount of material that can be
consumed by a mouse. However, this is not necessary when
using the plants of the present invention to vaccinate
humans, or other large mammals due to the volume which
can be consumed by the animal. Twenty-five micrograms of
the adjuvant should be applied directly to the com or
ryegrass before consumption when testing mice.
Intranasal immunization is accomplished in mice as follows. Mice are first lightly anesthetized with Isoflurane for
approximately 45 seconds. The immunizing inoculum (5-10
ml per animal/per dose) is delivered intranasally to the
external nares of one nostril with a pipette tip.
Oral immunization: Oral inoculations consisted of 500 ml
of the antigen preparation in saline delivered intragastrically
with a blunt-tip feeding needle (Popper & Sons, Inc.).
Sample collection: Animals are sacrificed following
euthanasia by C0 2 inhalation. Blood is collected by cardiac
puncture and the serum is separated in Microtainer tubes.
Bronchoalveolar lavages (BAL) are obtained by inserting a
20 G cannula in the exposed trachea and injecting 1 ml of
PBS supplemented with protease inhibitors. The buffer is
allowed to bathe the lung for approximately 20 seconds and
then it is suctioned out; this procedure is repeated three times
in each mouse. The resulting BAL fluid is immediately
centrifuged (400 g, 2 min, 4 ° C.) and the supernatant is
saved. To obtain nasal lavages a flexible 24 gauge canula is
inserted into the posterior opening of the nasopharynx and a
total of 150 ml ml PBS+ protease inhibitor is injected into
the opening. The outflow is collected as the nasal wash.
Vaginal washes are obtained by washing the vaginal mucosa
three times with 50 µI of PBS containing 0.01% NaN3 . For
determination of fecal IgA, feces are collected and frozen
overnight at - 70° C., lyophilized, resuspended in 800 µI PBS
containing 0.05% sodium azide per 15 fecal pellets, centrifuged at 1,400xg for 5 minutes, and the supernatant stored
at -20° C. until assayed.
Evaluation of humoral and mucosa! antibodies: Each
serum, BAL, nasal wash, vaginal wash, and fecal extract
sample is individually analyzed by ELISA. For all ELISA
assays, 96-well plates are coated with 500 ng per well of rPA
and incubated overnight at 4° C. All subsequent steps are

carried out at room temperature. After blocking with 1%
BSA, twofold serial dilutions of serum, BAL, nasal wash,
vaginal wash, or fecal extract from the experimental animals
are added. Alkaline phosphatase conjugated rabbit antimouse IgG or anti-mouse IgA are used for determination of
total IgG or IgA. Biotinylated anti-mouse IgGl, IgG2a,
IgG2b or IgG3 followed by alkaline phosphatase conjugated
streptavidin are used to quantify antibody isotypes. Optical
density at 405 nm is determined using an ELISA reader.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 2
<210>
<211>
<212 >
<213>

SEQ ID NO 1
LENGTH, 4
TYPE, PRT
ORGANISM, Bacillus anthracis

<400> SEQUENCE, 1
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-continued
Arg Lys Lys Arg
1

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 3
TYPE, PRT
ORGANISM, Bacillus anthracis

<400> SEQUENCE, 2
Phe Phe Asp
1

15

What is claimed is:
1. A plastid transformation vector for stably transforming
a plastid, said plastid vector comprising, as operably linked
components, a first flanking sequence, at least one regulatory
sequence operable in a plastid, a DNA sequence coding for
a protective antigen, a DNA sequence coding for a chaperonin, and a second flanking sequence.
2. A plastid transformation vector for stably transforming
a plastid, said plastid vector comprising, as operably linked

20

components, a first flanking sequence, at least one regulatory
sequence operable in a plaslid, a DNA sequence coding for
a protective antigen, a DNA sequence coding for a chaperonin, and a second flanking sequence, wherein said protective antigen is a bacterial antigen.
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